» Articles » PMID: 22633904

RETRACTED: Influence of Choroidal Neovascularization and Biodegradable Polymeric Particle Size on Transscleral Sustained Delivery of Triamcinolone Acetonide

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2012 May 29
PMID 22633904
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: One objective of this study was to determine whether polymeric nanoparticles and/or microparticles sustain transscleral choroidal and retinal delivery of triamcinolone acetonide (TA) for two months in therapeutically effective concentrations after single periocular administration. Another objective of this study was to assess the influence of choroidal neovascularization on transscleral delivery of TA.

Methods: Polymeric nano- and micro-particles of TA were prepared by o/w emulsion-solvent evaporation method using poly-l-lactide (PLA). Particles were characterized for drug loading, size, surface morphology, and the in vitro drug release profile. Choroidal neovascularization (CNV) was induced in brown Norway (BN) rats using a 532 nm diode argon laser and the CNV induction was assessed using fluorescein angiography. In vivo delivery was assessed in control and CNV induced rats at 2 months after periocular injection of TA loaded nano- or micro-particle suspension, or plain TA suspension in PBS (pH 7.4). Ocular tissue levels of TA were estimated using LC-MS/MS following liquid-liquid extraction of drug from tissue samples. Nile red loaded microparticles entrapped in periocular tissue at the end of the study was visualized using scanning electron microscopy and confocal microscopy. Inhibitory effect of TA on VEGF secretion was evaluated in ARPE-19 cells.

Results: Triamcinolone acetonide-PLA nano- (551 nm) and micro-particles (2090 nm), with 14.7 and 29.5% drug loading, respectively, sustained in vitro TA release for about 45 and 120 days. After subconjunctival injection, microparticles were able to sustain the delivery in all intraocular tissues for 2 months; whereas no drug levels were detected for TA loaded nanoparticles and plain suspension of TA. Intraocular delivery of TA from microparticles was higher in CNV induced rats when compared to control rats. Significant amount of microparticles remained in periocular tissue at 2 months after injection, and maintained spherical shape. TA decreased VEGF secretion by 50% at 0.07 μM. At the end of the in vivo study, choroid-RPE and retina TA levels in CNV induced rats were 16- and 5-fold higher than the IC(50) for VEGF secretion.

Conclusions: Single periocular injection of polymeric microparticles but not nanoparticles sustained effective levels of TA in choroid-RPE and retina for 2 months, with the TA delivery being greater in CNV induced rats than the control rats.

Citing Articles

Polymerization-Induced Phase Separation Formation of Structured Hydrogel Particles via Microfluidics for Scar Therapeutics.

Guo S, Kang G, Phan D, Hsu M, Por Y, Chen C Sci Rep. 2018; 8(1):2245.

PMID: 29396452 PMC: 5797090. DOI: 10.1038/s41598-018-20516-9.


Rationally designed nanocarriers for intranasaltherapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition.

Sallam M, Helal H, Mortada S Int J Nanomedicine. 2016; 11:2345-57.

PMID: 27307734 PMC: 4887068. DOI: 10.2147/IJN.S98547.


Particles from preformed polymers as carriers for drug delivery.

Miladi K, Ibraheem D, Iqbal M, Sfar S, Fessi H, Elaissari A EXCLI J. 2015; 13:28-57.

PMID: 26417241 PMC: 4464506.


Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Kompella U, Amrite A, Pacha Ravi R, Durazo S Prog Retin Eye Res. 2013; 36:172-98.

PMID: 23603534 PMC: 3926814. DOI: 10.1016/j.preteyeres.2013.04.001.


Nanotechnology approaches for ocular drug delivery.

Xu Q, Kambhampati S, Kannan R Middle East Afr J Ophthalmol. 2013; 20(1):26-37.

PMID: 23580849 PMC: 3617524. DOI: 10.4103/0974-9233.106384.


References
1.
Ozkiris A, Erkilic K . Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005; 40(1):63-8. DOI: 10.1016/S0008-4182(05)80119-X. View

2.
Nowak J . Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006; 58(3):353-63. View

3.
Nowak J, Bienias W . [Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies]. Postepy Hig Med Dosw (Online). 2007; 61:83-94. View

4.
Kadam R, Kompella U . Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther. 2009; 332(3):1107-20. PMC: 2835449. DOI: 10.1124/jpet.109.161570. View

5.
Jonas J, Kreissig I, Degenring R . Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003; 240(10):873-4. DOI: 10.1007/s00417-002-0547-y. View